Results 1 to 10 of about 2,610 (155)

FDX1 inhibits thyroid cancer malignant progression by inducing cuprotosis

open access: yesHeliyon, 2023
Cuprotosis is a recently identified cell death form that caused by intracellular copper accumulation and regulated by FDX1. This work aimed to explore the role of cuprotosis and the pivotal regulatory gene FDX1 in thyroid cancer development.
Gaoxiang Chen   +4 more
exaly   +5 more sources

Deep Mutational Scanning of FDX1 Identifies Key Structural Determinants of Lipoylation and Cuproptosis [PDF]

open access: yesNature Communications
Cuproptosis is a recently described form of regulated cell death triggered by ionophore-induced copper (Cu) overload in mitochondria. It is critically dependent on ferredoxin 1 (FDX1), a mitochondrial iron-sulfur cluster containing protein that acts as ...
Jeffrey C. Hsiao   +8 more
doaj   +4 more sources

LncRNA PVT1 promotes cuproptosis through transcriptional activation of FDX1 in colorectal cancer

open access: yesRedox Biology
Background: Cuproptosis, a copper-dependent form of regulated cell death, has emerged as a redox-sensitive vulnerability in cancer. However, the molecular basis by which this process is initiated and sustained in tumors remains poorly defined.
, Zhuoran Sun, Jingjing Jiang
exaly   +5 more sources

Ferrodoxin 1 (FDX1) drives paclitaxel resistance in ovarian cancer via copper metabolism and ULK1/ATG13-mediated autophagy: overcome by pH/ROS-responsive PPD/PDP@si-FDX1 nanomicelles [PDF]

open access: yesJournal of Experimental & Clinical Cancer Research
Background Ovarian cancer (OC) is often characterized by poor prognosis due to paclitaxel (TAX) resistance, with ferredoxin 1 (FDX1) emerging as a key mediator of copper metabolism.
Yangmei Gong, Zhizhi Deng, Jie Wu, Yi Hu
doaj   +2 more sources

Cuproptosis-related gene FDX1 expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma

open access: yesFrontiers in Immunology, 2022
BackgroundCuproptosis, a newly discovered form of cell death, is regulated by protein lipoylation and is related to mitochondrial metabolism. However, further research is needed to determine how the cuproptosis-related gene ferredoxin 1 (FDX1) affects ...
Tao Wang   +5 more
exaly   +3 more sources

Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma

open access: yesFrontiers in Immunology, 2022
BackgroundThe mechanism of copper-induced cellular death was newly discovered and termed cuproptosis. Inducing cuproptosis in cancer cells is well anticipated for its curative potential in treating tumor diseases.
Zhengang Hu, Quan Cheng
exaly   +3 more sources

Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker

open access: yesFrontiers in Genetics, 2022
Background: The latest research identified cuproptosis as an entirely new mechanism of cell death. However, as a key regulator in copper-induced cell death, the prognostic and immunotherapeutic value of FDX1 in pan-cancer remains unclear.Methods: Data ...
Chi Zhang   +7 more
exaly   +3 more sources

AT-101 inhibits the proliferation and invasion of tongue squamous carcinoma cells by targeting the miR-21-5p/FDX1 axis [PDF]

open access: yesScientific Reports
Tongue squamous cell carcinoma (TSCC) is an aggressive oral malignancy with an increasing incidence worldwide, however, the molecular regulatory mechanisms underlying its progression still unclear.
Shuai Fu   +4 more
doaj   +2 more sources

Emodin triggers cuproptosis to suppress hepatocellular carcinoma via SLC7A11/FDX1 axis [PDF]

open access: yesFrontiers in Oncology
BackgroundHepatocellular carcinoma (HCC) is a lethal malignancy with limited therapeutic options, necessitating novel treatment strategies. This study investigates the potential of emodin, a natural anthraquinone, to suppress HCC by inducing cuproptosis,
Yantong Chen   +6 more
doaj   +2 more sources

Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma

open access: yesCells, 2023
Background: Progress in the diagnosis and treatment of clear cell renal cell carcinoma (ccRCC) has significantly prolonged patient survival. However, ccRCC displays an extreme heterogenous characteristic and metastatic tendency, which limit the benefit ...
Aimin Jiang, Baohua Zhu, Juan Lu
exaly   +3 more sources

Home - About - Disclaimer - Privacy